Two FLT3 inhibitors, midostaurin (first generation) and gilteritinib (second generation), have recently been approved by the U.S. Food and Drug Administration (FDA) for use in patients with FLT3-mutated AML [52]. The gene discussed is FLT3; the disease is acute myeloid leukemia.